181 results on '"Denis, Louis J."'
Search Results
2. Abstract C003: RAMP 205: A phase 1b/2a study of gemcitabine, nab-paclitaxel, avutometinib, and defactinib in untreated metastatic pancreatic ductal adenocarcinoma
3. The Millenium Patients’ Perspective
4. Supplementary Data from ASN004, A 5T4-targeting scFv-Fc Antibody–Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models
5. Data from ASN004, A 5T4-targeting scFv-Fc Antibody–Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models
6. The Prevention of Prostate Cancer
7. Europa Uomo: The European Prostate Cancer Coalition
8. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up
9. Better Patients’ Perspective
10. Abstract CT204: A phase 1/2 study of VS-6766 in combination with sotorasib in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203)
11. ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of VS-6766 (RAF/MEK clamp) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).
12. A phase 2 study of VS-6766 (RAF/MEK clamp) RAMP 202, as a single agent and in combination with defactinib (FAK inhibitor) in recurrent KRAS mutant (mt) and BRAF mt non–small cell lung cancer (NSCLC).
13. Phase I trial of the RAF/MEK clamp VS-6766 in combination with everolimus using an intermittent schedule with expansion in NSCLC across multiple KRAS variants.
14. A phase 1/2 study of VS-6766 (RAF/MEK clamp) in combination with sotorasib (G12C inhibitor) in patients with KRAS G12C mutant non–small cell lung cancer (NSCLC) (RAMP 203).
15. Active surveillance for low-risk prostate cancer
16. Primary Endocrine Treatment of Advanced Prostate Cancer
17. CORRELATION BETWEEN STAGE SHIFT AND DIFFERENCES IN MORTALITY BETWEEN THE TWO STUDY ARMS OF THE ERSPC.: PD09-01
18. PD13-04 PROSTATE CANCER SPECIFIC MORTALITY IN THE ERSPC TRIAL: WHAT IS THE ROLE OF SCREENING RESULT AND ADHERENCE
19. ASN004, A 5T4-targeting scFv-Fc Antibody–Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models
20. Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine
21. Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies
22. Screening and prostrate-cancer mortality in a randomized European study
23. Prostate-Cancer Mortality at 11 Years of Follow-up
24. Abstract PR09: Phase 1 clinical safety and efficacy of ASN007, a novel oral ERK1/2 inhibitor, in patients with RAS, RAF or MEK mutant advanced solid tumors
25. Conclusions and reflections
26. Estrogens and aspects of prostate disease
27. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer
28. European randomized study of screening for prostate cancer: progress report of Antwerp and Rotterdam pilot studies
29. Report of the consensus workshop on screening and global strategy for prostate cancer
30. Clinical activity, safety and tolerability of ASN002, a dual JAK/SYK inhibitor, in patients with non-Hodgkin lymphoma (NHL), myeolfibrosis (MF), chronic lymphocytic leukemia (CLL) and solid tumors.
31. Abstract B147: A phase 1 PK/PD study of ASN003, a novel, highly selective BRAF and PI3K dual inhibitor, in patients with advanced solid tumors
32. ASN003, a highly selective BRAF and PI3K inhibitor: Preclinical and phase 1 clinical data in patients with advanced solid tumors.
33. Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1/2 clinical trial.
34. Clinical activity, safety and tolerability of ASN002, a dual SYK/JAK inhibitor, in patients non-Hodgkin lymphoma (NHL) and solid tumors.
35. ASN001, a novel CYP17 lyase inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC): Safety/tolerability and early activity in a multicenter phase 1/2 trial.
36. PD09-01 CORRELATION BETWEEN STAGE SHIFT AND DIFFERENCES IN MORTALITY BETWEEN THE TWO STUDY ARMS OF THE ERSPC.
37. Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening
38. First International Conference on Chemoprevention of Prostate Cancer
39. Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach
40. Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer
41. RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).
42. The Prevention of Prostate Cancer
43. Europa Uomo: The European Prostate Cancer Coalition
44. Development of a patient-reported outcome (PRO) measure for assessing non-small cell lung cancer (NSCLC) symptoms in clinical trials: Interim report from the PRO Consortium’s NSCLC Working Group (WG).
45. Endocrine treatment in prostate cancer
46. Prostate cancer from the horizon of the patient
47. Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine
48. Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
49. PD3-1-6: PF-3512676 (CPG 7909), a toll-like receptor 9 agonist-status of development for non-small cell lung cancer (NSCLC)
50. Estrogens and aspects of prostate disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.